S&P 500
7,376.86
+23.13
+0.31%
Dow
51,285.73
-237.37
-0.46%
Nasdaq
24,579.42
+264.42
+1.09%
NYSE Composite
23,950.37
-5.63
-0.02%
Russell 2000
2,754.11
+24.22
+0.89%
VIX
25.64
-2.54
-9.01%
AORT · Artivion, Inc.
NEW YORK STOCK EXCHANGE, INC. - BOATS Real Time Price • USD
$20.23
-4.91
(-19.51%)
● At close: November 6 at 4:00:00 PM EDT
DAY'S RANGE
$20.23
$19.75
$22.68
52-WEEK RANGE
$20.23
$19.16
$48.25
What's happening
- AORT is down 19.51% today, trading at $20.23. — Live quote
- Volume today (245,910) is well below its 3-month average of 646,620. (Finnhub fundamentals)
- Last quarter's EPS missed estimates: $-0.16 actual vs. $-0.06 estimated (-156.0%). (Finnhub earnings history)
Deterministic template sentences filled in from the same sourced figures shown elsewhere on this page -- not an AI-written summary, no live model call.
Key Statistics
Analyst Recommendations
Strong buy 6
Buy 8
Hold 1
Sell 0
Strong sell 0
Aggregate ratings for 2026-11-01 (15 analysts polled by Finnhub) — consensus count.
Performance Overview (Trailing returns vs S&P 500 benchmark)
YTD RETURN
AORT
-55.69%
vs S&P 500
-63.52%
1-YEAR RETURN
AORT
-57.45%
vs S&P 500
-67.15%
6-MONTH RETURN
AORT
-43.72%
3-MONTH RETURN
AORT
-25.48%
Earnings Trends (Quarterly EPS Actual vs Estimate)
2026-11-05 (Q3 2026)
$-0.16
Est. $-0.06
MISS -156.0%
2026-07-26 (Q2 2026)
$-0.28
Est. $0.01
MISS -2845.1%
2026-04-26 (Q1 2026)
$0.03
Est. $0.05
MISS -40.1%
2026-01-26 (Q4 2025)
$0.05
Est. $0.08
MISS -40.0%
Valuation Measures & Ratios
Enterprise Value4$1.28B
Forward P/E5—
PEG Ratio6—
Price / Sales (TTM1)2.09
Price / Book72.45
EV4 / Revenue2.70
EV4 / EBITDA44.37
Profit Margin-0.67%
Operating Margin2.89%
Return on Equity (ROE8)-0.71%
Return on Assets (ROA9)-0.34%
Avg Volume (3M)646,620
Quarterly history (5 periods)
| Measure | Sep '26 | Jun '26 | Mar '26 | Sep '25 | Jun '25 |
|---|---|---|---|---|---|
| Market cap | $1.13B | $1.09B | $1.73B | $2.12B | $1.40B |
| P/E | -83.72 | -255.57 | 197.48 | 418.71 | -391.18 |
| Price/Sales | 2.36 | 2.32 | 3.92 | 5.03 | 3.44 |
| Price/Book | 2.54 | 2.44 | 3.84 | 4.82 | 3.32 |
| EV/Revenue | 3.02 | 2.93 | 4.28 | 5.36 | 3.84 |
| EV/EBITDA | 37.05 | 32.12 | 36.41 | — | — |
| ROE | -3.03% | -0.95% | 1.94% | 1.15% | -0.85% |
| ROA | -1.30% | -0.40% | 0.99% | 0.59% | -0.43% |
Trailing-twelve-month ratios computed from SEC EDGAR quarterly figures and historical daily close prices (Alpaca). Diluted shares are derived from Net income ÷ EPS (diluted) for each quarter, not separately reported. Forward P/E/PEG unavailable (no free data source).
Glossary — what these abbreviations mean
- 1. TTM
- Trailing twelve months — the sum of the last four reported quarters, not a calendar year or the single latest quarter.
- 2. EPS
- Earnings per share — net income divided by diluted shares outstanding.
- 3. Beta
- A stock's historical volatility relative to the overall market. Above 1 means it has moved more than the market; below 1, less.
- 4. EV (Enterprise Value)
- Market cap plus total debt minus cash — roughly what it would cost to buy the whole company, debt included.
- 5. Forward P/E
- Price divided by analysts' estimated earnings for the next 12 months, instead of trailing actual earnings.
- 6. PEG Ratio
- P/E divided by expected earnings growth rate. A lower number can indicate a stock is cheap relative to how fast it's expected to grow.
- 7. Price / Book
- Share price divided by book value (assets minus liabilities) per share.
- 8. ROE
- Return on equity — net income divided by shareholders' equity, a measure of how efficiently a company turns equity into profit.
- 9. ROA
- Return on assets — net income divided by total assets, a measure of how efficiently a company turns assets into profit.
- 10. MRQ
- Most recent quarter — the single latest reported period, as opposed to TTM. The Financials section's "Quarterly" view below shows MRQ-style figures.
- 11. YoY
- Year over year — percent change versus the same period one year earlier, used for growth figures like those on Compare cards and the Screener.
Short Interest
Shares Short3,735,523
Change from Prior Settlement+3.15%
% of Float—
Days to Cover (Short Ratio)7.22
Source: FINRA Rule 4560 consolidated short interest, settlement date 2026-10-15. Reported bi-monthly with a reporting lag — not real-time.
Quotes and the 1-day extended-hours chart: Yahoo Finance. Longer historical charts: Alpaca (IEX feed) — real-time but IEX-only volume (~2.5% of consolidated market volume). Fundamentals + earnings: Finnhub.
Price history
Events
Drag horizontally to zoom into a section; use Reset view to restore all observations.
Technical signal summary
Calculating from the latest year of daily price history…
Show Technical Analysis Breakdown ▾ 10 Indicators
Not investment advice — read several signals together.
Indicators None active
Loading chart…
History limited by data provider; markers are heuristics, not signals.
Peer and sector context
No reviewed peer group is available for this symbol.
Balanced evidence
A deterministic summary of sourced facts—not an AI verdict.
Potential strengths
- Revenue growth is 11.3% on the provider's reported measure. Finnhub fundamentals ↗
- Latest SEC filing is Form 10-Q, filed 2026-11-06; review it for current changes and risks. SEC EDGAR ↗
Potential concerns
- Net profit margin is -0.7%. Finnhub fundamentals ↗
- Trailing 52-week price return is -57.5%. Finnhub market metrics ↗
Rule-based facts only; absence from either side is not evidence, and this is not a recommendation.
More on AORT
No accessible free API for these — links go to the source directly.
Financials
Fundamental trends
Visualized from the same SEC figures in the tables below.
Income statement
| Line item | Sep '26 | Jun '26 | Mar '26 | Sep '25 | Jun '25 | Mar '25 | Sep '24 | Jun '24 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $123.8M | $125.8M | $116.3M | $113.4M | $113.0M | $99.0M | $95.8M | $98.0M |
| Gross profit | $76.0M | $80.5M | $75.4M | $74.4M | $73.1M | $63.6M | $61.0M | $63.3M |
| Operating income | $2.9M | -$8.4M | $5.8M | $12.5M | $8.4M | $2.1M | $4.4M | $6.5M |
| Net income | -$7.9M | -$13.5M | $1.4M | $6.5M | $1.3M | -$505.0K | -$2.3M | -$2.1M |
| EPS (diluted) | $-0.16 | $-0.28 | $0.03 | $0.13 | $0.03 | $-0.01 | $-0.05 | $-0.05 |
| EPS (basic) | $-0.16 | $-0.28 | $0.03 | $0.14 | $0.03 | $-0.01 | $-0.05 | $-0.05 |
| Operating margin | $2 | -$7 | $5 | $11 | $7 | $2 | $5 | $7 |
| Net margin | -$6 | -$11 | $1 | $6 | $1 | -$1 | -$2 | -$2 |
Balance sheet
| Line item | Sep '26 | Jun '26 | Mar '26 | Dec '25 | Sep '25 | Jun '25 | Mar '25 | Dec '24 |
|---|---|---|---|---|---|---|---|---|
| Total assets | $1.04B | $1.07B | $883.2M | $884.8M | $857.7M | $838.4M | $791.2M | $789.1M |
| Total liabilities | $595.7M | $626.3M | $432.7M | $436.6M | $419.0M | $418.5M | $496.9M | $512.9M |
| Stockholders' equity | $446.4M | $445.6M | $450.5M | $448.2M | $438.7M | $419.9M | $294.3M | $276.2M |
| Total current assets | $338.8M | $371.4M | $357.5M | $358.1M | $337.5M | $318.8M | $287.3M | $290.1M |
| Total current liabilities | $76.7M | $106.9M | $92.7M | $101.6M | $85.8M | $66.7M | $51.9M | $66.8M |
| Cash & equivalents | $48.4M | $77.3M | $55.8M | $64.9M | $73.4M | $53.5M | $37.7M | $53.5M |
| Accounts receivable | $94.9M | $97.9M | $91.9M | $89.8M | $88.1M | $91.4M | $87.8M | $79.5M |
| Inventory | $107.1M | $103.4M | $98.0M | $92.4M | $90.5M | $86.7M | $81.9M | $79.8M |
| Property, plant & equipment | $81.7M | $73.7M | $67.7M | $65.0M | $40.7M | $40.1M | $37.8M | $36.4M |
| Goodwill | $345.0M | $349.9M | $251.7M | $254.1M | $254.0M | $253.8M | $245.1M | $241.0M |
| Intangible assets | $145.9M | $149.3M | $120.0M | $123.7M | $126.5M | $129.3M | $127.5M | $128.1M |
| Other non-current assets | $17.9M | $15.2M | $15.7M | $15.2M | $29.1M | $26.9M | $25.0M | $24.5M |
| Accounts payable | $17.6M | $20.9M | $18.3M | $16.0M | $16.5M | $19.4M | $11.7M | $18.0M |
| Accrued liabilities | $17.7M | $16.3M | $17.4M | $16.4M | $12.2M | $11.4M | $11.5M | $11.8M |
| Deferred revenue (current) | — | — | — | — | — | — | — | — |
| Short-term debt | $0 | $0 | $0 | $0 | $0 | $73.0K | $135.0K | $195.0K |
| Other current liabilities | $3.9M | $7.4M | $2.7M | $4.8M | $4.3M | $3.1M | $708.0K | $583.0K |
| Long-term debt | $363.8M | $363.4M | $215.4M | $215.1M | $214.9M | $215.5M | $314.6M | $314.2M |
| Other non-current liabilities | $11.4M | $9.2M | $9.2M | $9.1M | $9.3M | $9.0M | $8.3M | $8.1M |
| Common stock & paid-in capital | $503.0K | $502.0K | $500.0K | $493.0K | $488.0K | $486.0K | $442.0K | $434.0K |
| Retained earnings | -$71.5M | -$63.6M | -$50.1M | -$51.5M | -$53.9M | -$60.4M | -$61.8M | -$61.3M |
| Accumulated other comprehensive income (loss) | -$11.5M | -$12.5M | -$11.6M | -$2.7M | -$2.3M | -$2.8M | -$18.6M | -$24.9M |
Cash flow
| Line item | Sep '26 | Jun '26 | Mar '26 | Dec '25 | Sep '25 | Jun '25 | Mar '25 | Dec '24 |
|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$4.6M | -$1.3M | $1.2M | $19.6M | $22.3M | $15.0M | -$17.0M | $10.1M |
| Investing cash flow | -$13.0M | -$129.4M | -$10.5M | -$30.5M | -$4.6M | -$3.3M | -$3.6M | -$11.4M |
| Financing cash flow | -$11.3M | $152.4M | $463.0K | $2.4M | $2.3M | $2.6M | $3.9M | $174.0K |
| Free cash flow | -$17.6M | -$12.0M | -$6.8M | -$7.9M | $17.7M | $11.7M | -$20.6M | $8.7M |
| Capital expenditures | $13.0M | $10.7M | $8.0M | $27.5M | $4.6M | $3.3M | $3.6M | $1.4M |
| Depreciation & amortization | $7.3M | $6.7M | $6.3M | $5.8M | $5.7M | $5.5M | $5.4M | $6.3M |
| Share-based compensation | $6.2M | $8.2M | $8.4M | $4.1M | $6.1M | $6.1M | $8.0M | $2.7M |
| Deferred income taxes | — | — | — | $37.0K | — | — | — | $2.7M |
| Change in accounts receivable | — | — | — | — | — | — | — | — |
| Other investing activities | $0 | $3.0M | — | — | $0 | $0 | — | — |
| Dividends paid | — | — | — | — | — | — | — | — |
| Share repurchases | — | — | — | — | — | — | — | — |
| Debt issued | $0 | $148.9M | — | $0 | $0 | $0 | $0 | -$6.0M |
| Debt repaid | $0 | $0 | $0 | $3.0K | $73.0K | $68.0K | $66.0K | $66.0K |
| Tax withholding on stock comp | — | — | — | $0 | — | — | — | $0 |
| Other financing activities | -$222.0K | -$216.0K | -$210.0K | -$173.0K | -$173.0K | -$175.0K | -$178.0K | -$203.0K |
Income statement
| Line item | Dec '25 | Dec '24 | Dec '23 | Dec '22 | Dec '21 |
|---|---|---|---|---|---|
| Revenue | $441.3M | $388.5M | $354.0M | $313.8M | $298.8M |
| Gross profit | $284.2M | $248.8M | $229.2M | $202.5M | $197.5M |
| Operating income | $33.7M | $38.9M | $5.7M | $6.2M | $8.1M |
| Net income | $9.8M | -$13.4M | -$30.7M | -$19.2M | -$14.8M |
| EPS (diluted) | $0.21 | $-0.32 | $-0.75 | $-0.48 | $-0.38 |
| EPS (basic) | $0.22 | $-0.32 | $-0.75 | $-0.48 | $-0.38 |
| Operating margin | $8 | $10 | $2 | $2 | $3 |
| Net margin | $2 | -$3 | -$9 | -$6 | -$5 |
Balance sheet
| Line item | Dec '25 | Dec '24 | Dec '23 | Dec '22 | Dec '21 |
|---|---|---|---|---|---|
| Total assets | $884.8M | $789.1M | $792.4M | $762.8M | $793.1M |
| Total liabilities | $436.6M | $512.9M | $510.6M | $478.5M | $492.3M |
| Stockholders' equity | $448.2M | $276.2M | $281.8M | $284.3M | $300.7M |
| Total current assets | $358.1M | $290.1M | $280.7M | $247.3M | $247.7M |
| Total current liabilities | $101.6M | $66.8M | $57.9M | $49.7M | $45.0M |
| Cash & equivalents | $64.9M | $53.5M | $58.9M | $39.4M | $55.0M |
| Accounts receivable | $89.8M | $79.5M | $71.8M | $61.8M | $53.0M |
| Inventory | $92.4M | $79.8M | $82.0M | $74.5M | $77.0M |
| Property, plant & equipment | $65.0M | $36.4M | $38.4M | $38.7M | $37.5M |
| Goodwill | $254.1M | $241.0M | $247.3M | $243.6M | $250.0M |
| Intangible assets | $123.7M | $128.1M | $142.6M | $151.3M | $167.0M |
| Other non-current assets | $15.2M | $24.5M | $8.9M | $7.3M | $8.3M |
| Accounts payable | $16.0M | $18.0M | $13.3M | $12.0M | $10.4M |
| Accrued liabilities | $16.4M | $11.8M | $10.4M | $12.4M | $7.7M |
| Deferred revenue (current) | — | — | — | — | — |
| Short-term debt | $0 | $195.0K | $1.5M | $1.6M | $1.6M |
| Other current liabilities | $4.8M | $583.0K | $2.4M | $1.3M | $1.1M |
| Long-term debt | $215.1M | $314.2M | $305.5M | $306.5M | $307.5M |
| Other non-current liabilities | $9.1M | $8.1M | $7.3M | $7.0M | $6.5M |
| Common stock & paid-in capital | $493.0K | $434.0K | $426.0K | $418.0K | $414.0K |
| Retained earnings | -$51.5M | -$61.3M | -$47.9M | -$17.2M | $2.0M |
| Accumulated other comprehensive income (loss) | -$2.7M | -$24.9M | -$12.0M | -$21.6M | -$9.9M |
Cash flow
| Line item | Dec '25 | Dec '24 | Dec '23 | Dec '22 | Dec '21 |
|---|---|---|---|---|---|
| Operating cash flow | $39.9M | $22.2M | $18.8M | -$5.2M | -$2.6M |
| Investing cash flow | -$42.0M | -$28.2M | -$502.0K | -$10.7M | $5.7M |
| Financing cash flow | $11.3M | $2.2M | $865.0K | -$1.6M | -$12.2M |
| Free cash flow | $839.0K | $11.0M | $9.1M | -$15.9M | -$15.7M |
| Capital expenditures | $39.0M | $11.2M | $9.8M | $10.7M | $13.1M |
| Depreciation & amortization | $22.5M | $24.2M | $23.1M | $22.4M | $24.0M |
| Share-based compensation | $24.4M | $14.2M | $14.4M | $12.3M | $10.7M |
| Deferred income taxes | $37.0K | -$1.5M | -$1.3M | -$885.0K | -$5.8M |
| Change in accounts receivable | — | — | — | — | — |
| Other investing activities | — | — | $2.3M | $1.7M | $249.0K |
| Dividends paid | — | — | — | — | — |
| Share repurchases | — | — | — | — | — |
| Debt issued | $0 | $184.0M | $0 | $0 | — |
| Debt repaid | $210.0K | $211.8M | $2.8M | $2.8M | $2.8M |
| Tax withholding on stock comp | $0 | $0 | $559.0K | $1.8M | $1.9M |
| Other financing activities | -$699.0K | -$623.0K | -$537.0K | -$459.0K | -$561.0K |
Source: SEC EDGAR XBRL filings (10-Q/10-K), as originally tagged by the company. Quarterly cash flow is reconstructed by de-cumulating fiscal-year-to-date figures (how cash flow is tagged in 10-Qs); other quarterly lines are reported directly.
Institutional holders
SEC Form 13F filers holding AORT as of the latest reported quarter. 13F only covers investment managers with $100M+ in assets — this is not a complete ownership picture, and does not include insiders (see Recent SEC filings below) or non-13F-eligible holders.
Institutional ownership is not available for this symbol right now.
Insider activity
Directors, officers, and 10%+ owners' reported transactions from SEC Form 4. A filing reports a transaction; it does not by itself explain why it happened.
Source: SEC EDGAR Form 4 filings · checked 25 most recent filings · covers 2026-03-02 to 2026-09-10
Recent transactions
- Insiders have net sold 135,792 shares over the last 182 days, across 0 purchases and 9 sales.
- Most recent: GREEN ANDREW M (SVP, Regulatory and Quality) — Open market sale of 11,480 shares on 2026-09-10.
Deterministic template sentences filled in from the SEC Form 4 figures in the tables below -- not an AI-written summary, no live model call.
Insider purchases & sales, last 6 months
Purchases (open market)0 sh(0 txns)
Sales (open market)135,792 sh(9 txns)
Net Shares-135,792
Counts only open-market purchases (code P) and sales (code S) — grants, option exercises, tax withholding, and gifts are excluded since they aren't a market buy/sell decision.
Insider roster
| Name | Title | Most Recent Transaction | Date | Shares |
|---|---|---|---|---|
| GREEN ANDREW M | SVP, Regulatory and Quality | Open market sale | 2026-09-10 | 11,480 |
| Mackin James P | President & CEO | Open market sale | 2026-08-19 | 70,000 |
| Berry Lance A | EVP, COO, CFO & Treasurer | Open market sale | 2026-08-14 | 715 |
| Holloway Jean F | SVP, General Counsel | Open market sale | 2026-08-12 | 977 |
| SEMEDO ANTHONY B. | Director | Other acquisition/disposition | 2026-06-02 | 6,325 |
| Salveson Jon W | Director | Grant / award | 2026-05-18 | 7,576 |
| Hoff Elizabeth A | Director | Grant / award | 2026-05-18 | 7,576 |
| Burbank Jeffrey H | Director | Grant / award | 2026-05-18 | 7,576 |
| Bullock James | Director | Grant / award | 2026-05-18 | 7,576 |
| BEVEVINO DANIEL J | Director | Grant / award | 2026-05-18 | 7,576 |
| ACKERMAN THOMAS F | Director | Grant / award | 2026-05-18 | 7,576 |
| Borgstrom Marna P | Director | Grant / award | 2026-05-14 | 7,850 |
| Horton Amy | VP, Chief Accounting Officer | Open market sale | 2026-03-03 | 901 |
| Stanton Marshall S. | SVP, Clinical & MD Affair | Open market sale | 2026-03-03 | 2,149 |
| Davis John E | Chief Commercial Officer | Open market sale | 2026-03-03 | 4,573 |
Recent transactions
| Date | Insider | Title | Transaction | Shares | Price |
|---|---|---|---|---|---|
| 2026-09-10 | GREEN ANDREW M | SVP, Regulatory and Quality | Open market sale | 11,480 | $24.97 |
| 2026-09-03 | GREEN ANDREW M | SVP, Regulatory and Quality | Open market sale | 1,493 | $26.02 |
| 2026-09-02 | GREEN ANDREW M | SVP, Regulatory and Quality | Open market sale | 6,510 | $27.27 |
| 2026-08-19 | Mackin James P | President & CEO | Open market sale | 70,000 | $28.95 |
| 2026-08-14 | GREEN ANDREW M | SVP, Regulatory and Quality | Open market sale | 616 | $28.55 |
| 2026-08-14 | Berry Lance A | EVP, COO, CFO & Treasurer | Open market sale | 715 | $28.55 |
| 2026-08-12 | Holloway Jean F | SVP, General Counsel | Open market sale | 977 | $28.49 |
| 2026-06-11 | GREEN ANDREW M | SVP, Regulatory and Quality | Option exercise | 14,001 | $18.44 |
| 2026-06-11 | GREEN ANDREW M | SVP, Regulatory and Quality | Open market sale | 14,001 | $20.71 |
| 2026-06-11 | GREEN ANDREW M | SVP, Regulatory and Quality | Option exercise | 30,000 | $11.03 |
| 2026-06-11 | GREEN ANDREW M | SVP, Regulatory and Quality | Open market sale | 30,000 | $20.69 |
| 2026-06-02 | SEMEDO ANTHONY B. | Director | Other acquisition/disposition | 6,325 | $0.00 |
| 2026-06-02 | SEMEDO ANTHONY B. | Director | Other acquisition/disposition | 6,325 | $0.00 |
| 2026-05-18 | SEMEDO ANTHONY B. | Director | Grant / award | 7,576 | $0.00 |
| 2026-05-18 | Salveson Jon W | Director | Grant / award | 7,576 | $0.00 |
| 2026-05-18 | Hoff Elizabeth A | Director | Grant / award | 7,576 | $0.00 |
| 2026-05-18 | Burbank Jeffrey H | Director | Grant / award | 7,576 | $0.00 |
| 2026-05-18 | Bullock James | Director | Grant / award | 7,576 | $0.00 |
| 2026-05-18 | BEVEVINO DANIEL J | Director | Grant / award | 7,576 | $0.00 |
| 2026-05-18 | ACKERMAN THOMAS F | Director | Grant / award | 7,576 | $0.00 |
| 2026-05-14 | Borgstrom Marna P | Director | Grant / award | 7,850 | $0.00 |
| 2026-03-04 | Holloway Jean F | SVP, General Counsel | Open market sale | 8,962 | $38.00 |
| 2026-03-03 | Horton Amy | VP, Chief Accounting Officer | Open market sale | 901 | $37.78 |
| 2026-03-03 | Holloway Jean F | SVP, General Counsel | Open market sale | 3,843 | $37.78 |
| 2026-03-03 | Stanton Marshall S. | SVP, Clinical & MD Affair | Open market sale | 2,149 | $37.78 |
| 2026-03-03 | Davis John E | Chief Commercial Officer | Open market sale | 4,573 | $37.78 |
| 2026-03-03 | Berry Lance A | EVP, COO, CFO & Treasurer | Open market sale | 6,316 | $37.78 |
| 2026-03-03 | Mackin James P | President & CEO | Open market sale | 17,887 | $37.78 |
| 2026-03-02 | Horton Amy | VP, Chief Accounting Officer | Grant / award | 7,475 | $0.00 |
| 2026-03-02 | Holloway Jean F | SVP, General Counsel | Grant / award | 27,795 | $0.00 |
| 2026-03-02 | Stanton Marshall S. | SVP, Clinical & MD Affair | Grant / award | 21,838 | $0.00 |
| 2026-03-02 | Davis John E | Chief Commercial Officer | Grant / award | 28,845 | $0.00 |
| 2026-03-02 | Berry Lance A | EVP, COO, CFO & Treasurer | Grant / award | 40,874 | $0.00 |
| 2026-03-02 | Mackin James P | President & CEO | Grant / award | 116,948 | $0.00 |
| 2026-03-02 | Horton Amy | VP, Chief Accounting Officer | Open market sale | 641 | $38.02 |
| 2026-03-02 | Stanton Marshall S. | SVP, Clinical & MD Affair | Open market sale | 1,513 | $38.02 |
| 2026-03-02 | Mackin James P | President & CEO | Open market sale | 14,911 | $38.02 |
Recent SEC filings
Official company reports and insider transaction filings. Form 4 reports a transaction; it does not by itself explain why it happened.
Source: SEC EDGAR submissions · updated 2026-11-09 02:45 UTC
| Filed | Form | Report period | Official filing |
|---|---|---|---|
| 2026-11-06 | 10-Q | 2026-09-30 | View on SEC.gov → |
| 2026-11-05 | 8-K | 2026-11-05 | View on SEC.gov → |
| 2026-09-11 | 4 | 2026-09-10 | View on SEC.gov → |
| 2026-09-04 | 4 | 2026-09-02 | View on SEC.gov → |
| 2026-08-20 | 4 | 2026-08-19 | View on SEC.gov → |
| 2026-08-17 | 4 | 2026-08-14 | View on SEC.gov → |
| 2026-08-17 | 4 | 2026-08-14 | View on SEC.gov → |
| 2026-08-12 | 4 | 2026-08-12 | View on SEC.gov → |
| 2026-08-07 | 10-Q | 2026-06-30 | View on SEC.gov → |
| 2026-08-06 | 8-K | 2026-08-06 | View on SEC.gov → |
| 2026-06-15 | 4 | 2026-06-11 | View on SEC.gov → |
| 2026-06-04 | 4 | 2026-06-02 | View on SEC.gov → |
Recent news
Headlines about AORT (Artivion, Inc.). Links open the publisher — we don’t host full articles.
-
Is Artivion (AORT) Undervalued Following Mixed Earnings And A Return To Losses?
Yahoo · 2026-11-07 -
Artivion Q3 Earnings Call Highlights
Yahoo · 2026-11-07 -
Freedom Capital Calls Artivion's Q3 Revenue a “Low-Quality Beat” as AORT Shares Drop 20%
GuruFocus · 2026-11-06 -
$AORT stock is down 20% today. Here's what we see in our data.
Quiver Quantitative · 2026-11-06 -
Artivion Inc (CYL.HA) Interactive Stock Chart - Yahoo Finance
Yahoo! Finance Canada · 2026-11-06 -
Artivion Inc (CYL.HA) latest stock news and headlines
Yahoo Finance Australia · 2026-11-06 -
Canaccord Genuity Maintains Buy on Artivion, Lowers Price Target to $30
Benzinga · 2026-11-06 -
Canaccord cuts Artivion stock price target on revenue outlook By Investing.com
Investing.com Nigeria · 2026-11-06
No headlines in this category right now — try “All”.